Wall Street Zen lowered shares of Microbot Medical (NASDAQ:MBOT – Free Report) from a sell rating to a strong sell rating in a report issued on Saturday,Wall Street Zen reports.
A number of other brokerages have also weighed in on MBOT. Zacks Research lowered shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Microbot Medical in a research note on Wednesday, July 8th. B. Riley Financial restated a “buy” rating and issued a $4.00 target price (down from $5.00) on shares of Microbot Medical in a research report on Friday, August 14th. HC Wainwright restated a “buy” rating on shares of Microbot Medical in a research report on Wednesday, August 19th. Finally, Loop Capital set a $4.00 price target on Microbot Medical in a research report on Wednesday, June 3rd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Microbot Medical presently has a consensus rating of “Hold” and a consensus target price of $6.38.
Read Our Latest Research Report on MBOT
Microbot Medical Stock Performance
Microbot Medical (NASDAQ:MBOT – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.08). The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.13 million. Research analysts forecast that Microbot Medical will post -0.29 earnings per share for the current year.
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in Microbot Medical by 14.3% in the third quarter. Vanguard Group Inc. now owns 2,343,561 shares of the biotechnology company’s stock worth $7,148,000 after acquiring an additional 292,923 shares during the period. CIBC Private Wealth Group LLC raised its position in Microbot Medical by 1.8% in the fourth quarter. CIBC Private Wealth Group LLC now owns 1,480,000 shares of the biotechnology company’s stock valued at $2,960,000 after purchasing an additional 26,000 shares during the period. CIBC Bancorp USA Inc. acquired a new position in shares of Microbot Medical in the 3rd quarter valued at $4,435,000. Geode Capital Management LLC lifted its stake in shares of Microbot Medical by 54.4% in the 4th quarter. Geode Capital Management LLC now owns 761,995 shares of the biotechnology company’s stock valued at $1,524,000 after purchasing an additional 268,609 shares during the last quarter. Finally, DNB Asset Management AS grew its holdings in shares of Microbot Medical by 178.1% during the 4th quarter. DNB Asset Management AS now owns 677,498 shares of the biotechnology company’s stock worth $1,355,000 after purchasing an additional 433,869 shares during the period. 16.30% of the stock is currently owned by institutional investors and hedge funds.
About Microbot Medical
Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.
Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.
Featured Stories
- Five stocks we like better than Microbot Medical
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
